• 1. An integrated digital microfluidic chip for multiplexed proteomic sample preparation and analysis by MALDI-MS?
  Hyejin Moon,Aaron R. Wheeler,Robin L. Garrell,Chang-Jin “CJ” Kim Lab Chip, 2006,6, 1213-1219
• 2. Acetylcholinesterase amperometric detection system based on a cobalt(II) tetraphenylporphyrin-modified electrode
  Analyst, 1996,121, 1123-1126
• 3. An integrated microfluidic platform for sensitive and rapid detection of biological toxins?
  Robert J. Meagher,Anson V. Hatch,Ronald F. Renzi,Anup K. Singh Lab Chip, 2008,8, 2046-2053
• 4. Acentric and chiral heterometallic inorganic–organic hybrid frameworks mediated by alkali or alkaline earth ions: synthesis and NLO properties
  Huabin Zhang,Shaowu Du CrystEngComm, 2014,16, 4059-4068
• 5. An artificial enzyme cascade amplification strategy for highly sensitive and specific detection of breast cancer-derived exosomes?
  Huiying Xu,Lu Zheng,Yu Zhou,Bang-Ce Ye Analyst, 2021,146, 5542-5549

Recent Advances in the Application of (1R,3S)-3-Aminocyclopentanol (CAS: 1110772-05-8) in Chemical Biology and Pharmaceutical Research

The compound (1R,3S)-3-Aminocyclopentanol (CAS: 1110772-05-8) has recently emerged as a key chiral building block in pharmaceutical synthesis and chemical biology research. This stereospecific aminocyclopentanol derivative has shown remarkable versatility in drug discovery programs, particularly in the development of novel enzyme inhibitors and receptor modulators. Recent studies highlight its unique structural features that enable precise spatial orientation of pharmacophores, making it particularly valuable for targeting complex protein binding sites.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the application of (1R,3S)-3-Aminocyclopentanol in the synthesis of potent histone deacetylase (HDAC) inhibitors. The researchers utilized the rigid cyclopentane scaffold to constrain the conformation of the zinc-binding group, resulting in improved selectivity for HDAC6 over other isoforms. The CAS 1110772-05-8 derivative showed 15-fold greater potency compared to linear analogs in cellular assays, suggesting significant advantages in drug design for epigenetic therapies.

In the field of antibiotic development, a recent patent application (WO2023056121) describes novel β-lactamase inhibitors incorporating (1R,3S)-3-Aminocyclopentanol as a core structural element. The compound's stereochemistry was found to be critical for maintaining optimal hydrogen bonding with key residues in the enzyme active site. This application demonstrates the growing importance of CAS 1110772-05-8 in addressing antimicrobial resistance challenges through rational drug design approaches.

Significant progress has also been made in the synthetic methodology for (1R,3S)-3-Aminocyclopentanol production. A 2024 publication in Organic Process Research & Development reported an improved asymmetric synthesis route with 92% enantiomeric excess and 85% overall yield, addressing previous scalability challenges. This advancement is particularly important as demand increases for this chiral synthon in both academic and industrial research settings.

Emerging applications in radiopharmaceuticals have been reported, where (1R,3S)-3-Aminocyclopentanol serves as a versatile scaffold for PET tracer development. Researchers at Massachusetts General Hospital recently developed a series of 18F-labeled analogs for imaging neuroinflammation, leveraging the compound's ability to cross the blood-brain barrier while maintaining metabolic stability. This represents an exciting new direction for CAS 1110772-05-8 derivatives in diagnostic applications.

The pharmaceutical industry has shown increasing interest in this compound, with several major companies including it in their fragment-based drug discovery libraries. Analysis of recent patent filings indicates a 40% increase in mentions of (1R,3S)-3-Aminocyclopentanol derivatives since 2021, particularly in oncology and CNS drug development programs. This trend suggests that the unique properties of CAS 1110772-05-8 will continue to drive innovation in drug design for the foreseeable future.

Future research directions for (1R,3S)-3-Aminocyclopentanol appear to focus on three main areas: development of more efficient synthetic routes, exploration of its applications in PROTAC technology, and investigation of its potential in RNA-targeted therapeutics. The compound's rigid yet functionalizable structure makes it particularly suitable for these cutting-edge approaches in chemical biology and medicinal chemistry.

• 124555-33-5(trans-3-Aminocyclopentanol hydrochloride)
• 946593-67-5((1S,3S)-3-Aminocyclopentanol)
• 1279032-31-3((1R,3S)-3-aminocyclopentanol;hydrochloride)
• 124555-42-6(cis 3-aminocyclopentanol)
• 946826-74-0((1R,3R)-3-aminocyclopentanol)
• 1284248-73-2(cis-3-aminocyclopentanol hydrochloride)
• 13725-38-7(3-Aminocyclopentanol)
• 167298-58-0(trans-3-Aminocyclopentanol)
• 1036260-18-0((1S,3R)-3-aminocyclopentanol)
• 1259436-59-3((1S,3R)-3-aminocyclopentanol;hydrochloride)